PerkinElmer this week announced that it has acquired Improvision, a privately held provider of cellular-imaging software and integrated hardware products.
PerkinElmer, which paid an undisclosed cash sum for the Coventry, UK-based company, hopes the acquisition will help it continue developing its portfolio of cellular-analysis tools.
The acquisition will expand PerkinElmer’s presence in the cellular analysis space from basic microscopy through confocal and high-content imaging, and enable it to develop additional cellular-science software, according to Mary Duseau, global sales leader of molecular medicine at PerkinElmer Life and Analytical Sciences.
Duseau told Cell-Based Assay News in an e-mail this week that PerkinElmer plans to incorporate Improvision’s Volocity 3D software into its cellular analysis platforms.
PerkinElmer is also “investigating several options for continued expansion in the cellular reagent space,” she said.
Improvision employs 42 people and generated more than £6 million ($11.9 million) in revenue last year.
Expanding the Portfolio
According to Duseau, PerkinElmer has had “a lot of previous experience” with Improvision’s Volocity 3D imaging package, which it has been selling as part of its UltraVIEW Live Cell Imaging system for more than five years.
“The Volocity software package is unique in that it has been focused on 3D imaging, in comparison to several others in this space that are really a 2D software package,” said Duseau, adding that it allows investigators to process 3D images in real-time.
“I think that the Volocity software and the people and application support at Improvision combine nicely with PerkinElmer’s recent acquisitions of Evotec and Euroscreen (see CBA News 12/1/2006 and CBA News 12/22/2006),” said Duseau. “If we look at our recent acquisitions, Evotec gaves us a center of excellence for R&D in cellular imaging capabilities. Now Improvision gives us a center of excellence for R&D in cellular-imaging software.”
“Now Improvision gives us a center of excellence for R&D in cellular imaging software.”
Duseau said that PerkinElmer plans to integrate its own sales and service organizations with Improvision’s around the cellular-imaging space.
When asked about a possible name change, Duseau said that PerkinElmer’s current strategy “is to understand how we can best serve our customers and combine the brand recognition that Improvision has into that of PerkinElmer.”
Duseau said that there are no immediate plans for personnel changes, adding that PerkinElmer plans to support all of Improvision’s products and evolve its portfolio to better serve its cellular-imaging customers.
According to Duseau, PerkinElmer will continue to look at other opportunities in the cellular sciences, from tools for basic microscopy applications to high-content screening technologies.
Andrew Waterfall, general manager of Improvision, said he believe’s that “there will definitely be further opportunities given the scale of the combined organization.”
PerkinElmer does not see gaps in its cellular portfolio, per se, Duseau said, although the company is “investigating several options for continued expansion in the cellular reagent space.”